The solution was to develop the first digital health platform using N=1 analytics to enable personalized measurement of therapeutic response and identification of disease modifying life-style factors. The Company’s first product is N1‑Headache™, which is indicated for migraine and is being used in multiple clinical studies.

Previously, Dr. Mian was CEO and a co-founder of Genmedica Therapeutics SL, a biotechnology company founded in 2005 in Barcelona, Spain to develop therapeutics for metabolic diseases such as type 2 diabetes. Under Dr. Mian’s leadership, Genmedica developed one of the few novel approaches for developing drugs that target disease pathogenesis rather than just symptoms. Using this approach Genmedica became one of Spain’s leading biotechnology startups, closing Spain’s largest life-science financing round in 2012. Genmedica’s compounds are currently in phase II clinical trials.

Before that, Dr. Mian was CEO and co-founder of Gamera Biosciences Corporation in Boston, USA which was founded in 1993 to develop high-speed, microfluidics technology for the drug discovery and genomics industries. The company was financed by local and international venture capital sources. In 1999 Gamera was sold to Tecan Ltd (SWX: TECN), a publicly-traded Swiss biomedical company.

Dr. Mian completed his Bachelors in biology at McGill University in Montreal, Canada. He completed his doctorate in genetics at University of Cambridge, UK, with Dr. Gabriel Dover; and Harvard Medical School, Boston, USA, with Dr. George Church. He is author or co-author of dozens patents and publications. Dr. Mian is a citizen of Germany and Canada.

Previously, Mr. Verdura spent 12 years at Novartis Pharma. Up to 2016, he was Global Head of Digital Solutions. In this role, he was responsible for designing and executing the digital strategy for the Immunology and Dermatology business unit, as well as for developing digital solutions in conjunction with the global commercial and development teams. He was also Global Head of CRM Operations in 2010, responsible for designing and implementing a CRM strategy and support model globally, as well as overseeing the implementation of a new CRM system.

Prior to Novartis and until 2005 he worked at different consulting firms in the US, Mexico and Europe, such as KPMG, Deloitte and Cap Gemini, as well as being a freelance consultant in the area of management consulting and ERP across different industries.

In 2010 Mr. Verdura received executive education at IMD Business School, Lausanne, Switzerland and in 1994 received a B.S. in Industrial Engineering from Tecnológico de Monterrey (ITESM) in Mexico City.

He has worked as a drug development consultant to multiple companies over the past 9 years, including Genmedica Therapeutics. Previously he was VP Clinical Research Europe and head of the European development function with Elan Corporation, as well as global project leader, and played major roles in the development of products including: Tysabri (multiple sclerosis and Crohn’s disease), Neurobloc (torticollis), Zelepar (Parkinson’s disease), Zonegran (epilepsy) and Prialt (severe pain).

Prior to Elan Stephen was Senior Clinical Research Manager at Glaxo where he led an international team conducting phase 3 trials of sumatriptan for migraine - the first in class of the triptans which became a multi-billion dollar product. He was also clinical leader for the diabetes drug Troglitazone.

Stephen holds B.Sc. and Ph.D. degrees from Leeds University, UK and undertook post-doctoral academic research and teaching at Birmingham University and the Royal Free Hospital, London. Dr. Donoghue is a citizen of the UK.

Amparo has contributed to the design and publication of over a hundred research studies in multiple therapeutic areas, primarily cardiology (cardiovascular prevention, arrhythmias, acute coronary syndromes, interventional cardiology), neurology (stroke, neuroimaging), and endocrinology (diabetes). Her contributions to the advancement of clinical trials methodology, particularly in the area of sample size calculations for complex designs (cluster crossover trials), have been published and presented in international conferences.

Dr. Casanova obtained and MD (Faculty of Medicine) and PhD (Department of Statistics) from the University of Barcelona (Spain). She practiced medicine (occupational health) for seven years before joining the Department of Public Health in the University of Barcelona, to pursue her passion: a career in research. She has worked in the University of Barcelona (Spain), and the Universities of Toronto and McMaster (Canada). Amparo is a member of the Society for Clinical Trials, and of the Statistical Society of Canada.

She is also a visiting professor at the Universitat de Girona (Spain).

Marina Vives-Mestres studied Industrial Engineering at the Universitat Politècnica de Catalunya (UPC) in Barcelona (Spain) within the framework of a double diploma with the Institut des Sciences Appliquées de Lyon (France). She earned her Masters degree on Statistics and Operational Research (UPC and Universitat de Barcelona); became certified as a Six Sigma Black Belt; and completed a PhD on statistics applied to process monitoring at the Universitat de Girona.

She is the recipient of two awards from the European Network for Business and Industrial Engineering for the best student presentation (2015) and for the best presentation made by a non-academic (2018).

He is a multidisciplinary designer with over 24 years experience working as a team leader or individual contributor. His career has encompassed fields as diverse as brand design and corporate identity, signage, packaging, editorial design, product design, museum design, and interactive digital media.

From 1999-2002 he was art director at Barcelona McCann & Erickson Worldwide, a world leader in advertising and communications for global companies. From 2002 to 2007, he was founder and CEO of Gruyere-bcn, a corporate communication studio with a team of eleven designers involved in a wide range of design and communication projects. At the same time, from 2002 to 2007 he was also Art Director at Angle Publishing House and La Evolución Barcelona (lighting company). Prior to joining Curelator in 2013, he performed freelance branding work for national and international corporate clients.

Mr. Albert’s education encompasses the world of corporate, product and software UI/UX design as well as marketing. He has a graduate degree in graphic design at EASDVic 1992-1997, Master in multimedia interface design at Elisava Barcelona 1999-2000, Human Computer Interaction in 2014 from London Nielsen Norman Group and Human-Computer Interaction for User Experience Design in 2019 from MIT (Massachusetts Institute of Technology); and a marketing degree from Esade Business School, Barcelona, in Spain, in the marketing management Program, 2008-2009.

Mr. Albert is a citizen of Catalunya, Spain.

In 2002, he co-founded what became Amiral Agence Web, a web development and marketing agency based in Quebec City. During his 11 years at the agency, he contributed to the success of the company as software developer, team lead and technical director.

He joined Curelator in 2013 to act as technical lead, building and managing the development team to launch the first version of the product. In 2016, he additionally took on the role of innovation lead, to address the emerging needs of the company in data science, data security and privacy, and product management.

Gabriel studied Computer Science, focusing on web and internet applications, at Université Laval in Quebec City.

Broadly speaking, he helped us develop a superior way to identify and measure the factors associated with debilitating episodic attacks in individuals (not simply populations, as is standard) with chronic disease. For N1‑Headache™, specifically, he helped develop and implement our N=1 data approach, which unscrambles the wide range of factors associated with increasing and decreasing (also new concept) the risk of migraine attack on an individual basis.

As a direct result of his work, the N1‑Headache™ N-1 approach is still a bit ahead of its time. We don’t yet have competitors who are focusing on identifying - for each individual user - the things that make them feel worse or better, and enabling that person to act upon this information and then measure the results to determine whether adding or subtracting certain behaviors or foods might lessen the frequency or severity of their attacks.

Francesc was a dominant figure in statistical analysis in Spain, working on clinical trials for COPD, allergic rhinitis, schizophrenia, drug addiction, multiple sclerosis, alternatives to nephrostomy, and of course, migraine. He was 65 years old. We will miss him. Godspeed Francesc.

Peris F, Donoghue S, Torres F, Mian A, Wöber C.
Towards improved migraine management: Determining potential trigger factors in individual patients.
Cephalalgia 2017 Apr; 37(5): 452-463
Donoghue S, Mian A, Albert M, Boucher G, Peris F, Wöber C.
Identification of ‘protectors’ against migraine attacks using N1‑Headache™.
Cephalagia. 2016;Vol. 36(1S) 1–185